Table 3.
Adverse events of sorafenib treatment
| Sorafenib (n=58) | Combination Tx (n=22) | p-value | |||
|---|---|---|---|---|---|
| All grade | Grade 3/4 | All grade | Grade 3/4 | ||
| Diarrhea | 9 (15.5) | 0 | 4 (18.2) | 0 | 0.51 |
| HFSR | 39 (67.2) | 7 (12.1) | 15 (68.2) | 3 (13.6) | 0.58 |
| Fatigue | 7 (12.1) | 0 | 3 (13.6) | 0 | 0.56 |
| Nausea/vomiting | 3 (5.2) | 0 | 2 (9.1) | 0 | 0.42 |
| Anorexia | 8 (13.8) | 0 | 3 (13.6) | 0 | 0.63 |
| Hypertension | 12 (20.6) | 1 (1.7) | 3 (13.6) | 0 | 0.35 |
| Alopecia | 9 (15.5) | 0 | 4 (18.2) | 0 | 0.51 |
| Elevated ALT | 7 (12.1) | 1 (1.7) | 9 (40.9) | 2 (9.1) | 0.01 |
| Elevated Amy | 15 (25.9) | 2 (3.4) | 4 (18.2) | 1 (4.5) | 0.34 |
| Hyperbilirubinemia | 3 (5.2) | 0 | 2 (9.1) | 0 | 0.42 |
| Rash | 5 (8.6) | 5 (8.6) | 2 (9.1) | 2 (9.1) | 0.63 |
| Leukocytopenia | 4 (6.9) | 1 (1.7) | 4 (18.2) | 1 (4.5) | 0.14 |
| Thrombocytopenia | 10 (17.2) | 2 (3.4) | 7 (31.8) | 1 (4.5) | 0.13 |
Note: Results reported as number (%).
Abbreviations: Tx, therapy; HFSR, hand–foot skin reaction; ALT, alanine aminotransferase; Amy, amylase.